Fischer Hearing Centre – Behavioural signs of hearing loss

Regina Watch
Hearing care is health care. Candace Fischer takes us through some behavioural signs and why you should get your hearing tested. #SponsoredContent

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

CBC

an hour ago

• CBC

How an Indigenous health centre in Montreal is making care more welcoming

As Shirley Pien-Bérubé walks through the halls of the Indigenous Health Centre of Tio'tia:ke, she pauses to point out all the ways the Montreal-based clinic has grown since it opened in 2023. "Our services have expanded so much," she said. "We have a diabetic foot-care clinic, we have an optometry clinic, physiotherapy, mental health, clinical psychologist, addictions worker, a spiritual healer." Just inside the main entrance, a table is set up with sage and sweetgrass. Patients are invited to smudge or make their own medicine bundles. Care here is offered in several Indigenous languages, including Inuktitut and Cree. Pien-Bérubé works as a health navigator, accompanying patients and advocating for them within the health-care system. She says that's just one of the services offered here. The clinic aims to close gaps in health outcomes for Indigenous patients, which was one of the 94 calls to action of Canada's Truth and Reconciliation Commission (TRC). Clinic staff also work to overcome deep-rooted mistrust in the health-care system. Data from a recent Statistics Canada survey found about one in five Indigenous people reported experiencing unfair treatment, racism or discrimination from a health-care professional over the previous year. Pien-Bérubé says patients at her clinic can feel safe and understood. "They are finally being heard — after how many centuries? We are finally being heard," she said. Indigenous clinic aims to close gaps outlined by TRC 7 hours ago Duration 2:14 10 years after TRC's calls to action It's been 10 years since the Truth and Reconciliation Commission, which looked to document the impact of residential schools, released its final report. In it, the commissioners pointed to "troubling gaps in health outcomes between Aboriginal and non-Aboriginal Canadians." Those include disparities in the rates of infant mortality, diabetes and suicide. Seven of the TRC's 94 calls to action focused on health, including a call to identify and close gaps in health outcomes, funding for existing and new Indigenous healing centres and recognizing the value of Indigenous healing practices. Fay Virginia Desjarlais, the family violence prevention co-ordinator at the Indigenous Health Centre of Tio'tia:ke, says the clinic is a sign there has been some progress. "There were gaps in the health system to really understand the needs of the Indigenous people living in Montreal," she said. "People didn't feel safe. A lot of advocates, elders and different organizations came together to say 'We need to do something.' " Desjarlais says hospitals and other health-care settings can be unwelcoming for many Indigenous people. She has seen patients face discrimination and racism, and has been through it herself with a family doctor. "I'm diabetic and I was explaining that I'm not feeling well," she said, adding that when she described her symptoms, the doctor replied that when people feel that way, "that's because you're drinking." She says the doctor then dropped her as a patient because she had missed a single appointment. "I couldn't believe it," Desjarlais said. Improving access to health care According to the website Indigenous Watchdog, which tracks progress on the calls to action, while four of the seven calls related to health are in progress, three have stalled, and none are complete. The site's publisher, Douglas Sinclair, says the call to identify and close gaps around health outcomes has stalled in part due to a lack of access to government data. "There's just no political will across the country to sort of co-ordinate activities to identify that information and make it available," Sinclair said. "You can't develop policy if you're working in a vacuum." The federal government tracks its response to the recommendations on its website. It includes a health inequalities data tool available for users to visualise and "understand the size of inequities in social determinants of health and health outcomes." Sinclair says that where there has been progress, it hasn't been enough. He says access to health care remains a major issue for a lot of communities. Building treatment centres in the North In Iqaluit, Nunavut, an addictions and trauma treatment centre called Aqqusariaq is currently under construction that will allow people to receive culturally-based treatment in the territory, in Inuktitut, rather than having to travel south. "Travelling all the way down south to have to take part in treatment and care, you are being removed from your language and culture," said Kylie Aglukark, program director with addictions and trauma at Nunavut Tunngavik Incorporated, a treaty organization that represents Inuit in Nunavut. "I'm hopeful that once this is up and running that we have an opportunity to build centres in each of Nunavut's regions," she said. Beyond that, Aglukark wants to build up the Inuit workforce for the centre and other services and to establish more treatment centres in more communities. "It's very important for Inuit to lead and have that opportunity to provide the services in Inuktitut," she said. Dr. Terri Aldred, academic lead with the National Collaborating Centre for Indigenous Health, says progress on the calls to action around health has been "moderate." While she's impressed with new Indigenous health clinics and healing centres like the ones in Montreal and Iqaluit that are "rooted in our ways of knowing and being," Aldred says such projects need to be scaled up to meet the need. She says they also need sustainable, long-term funding. "Indigenous people that are able to access those services will start to have a different relationship with accessing health care," she said. "And we'll be able to build trust with those providers, and we'll have a positive ripple effect.

CBC

an hour ago

• CBC

National vaccine registry needed amid measles resurgence, Canada's outgoing top doctor says

As Dr. Theresa Tam retires as Canada's top doctor, she's calling for a national vaccine registry. Tam says the COVID-19 pandemic, which began in early 2020 and killed at least 60,000 Canadians, showed how badly one is needed to track vaccines and protect vulnerable communities. A national vaccine registry, she says, could help prevent and manage crises like the resurgence of measles that the country now faces. Tam says she's in favour of a "nationally interoperable network of vaccine registries" that connects all of the provincial and territorial health systems and helps identify pockets of the population where there is poor vaccine coverage. While the majority of measles cases so far have occurred in communities that are historically under-vaccinated, she told Dr. Brian Goldman, host of CBC's White Coat, Black Art, "we don't actually know exactly where the situation with vaccine coverage lies." Tam spoke to Goldman from Ottawa for a feature interview reflecting back on her career as the country's chief public health officer. The pandemic proved that the technology for a registry is there, she says, given that almost all provinces and territories made COVID-19 vaccine records available electronically during that time. Although it was the pandemic that made her both a household name — and a target for hate — Tam came to the role of top doctor three years earlier, in June 2017, after occupying a series of other leadership positions within the Public Health Agency of Canada (PHAC), including deputy chief. She has also served as an expert on a number of World Health Organization committees. WATCH | Dr. Theresa Tam on facing personal attacks during the pandemic: Leading Canada's public health response to COVID-19 was as much a personal challenge as it was a professional one, given Tam was also on the receiving end of racist and sexist vitriol during that time. "What I try to do, certainly at the time and even now, is just to focus on the job that I'm trying to deliver," she said. Those attacks were even harder on her staff — those monitoring the channels where the messages would come in, and who tried, as much as possible, to shield her from the worst of it, Tam says. "And one member of my staff used to also read me the incredibly lovely cards and messages that the public sent to encourage me to carry on. It was like the antidote to the other messages as well. So that really helped." One of Tam's provincial counterparts, Dr. Robert Strang, chief medical officer of health in Nova Scotia, says he has "huge respect for Dr. Tam." "Certainly working with her during COVID, we were all kind of in this kind of team together. Having her leading us as chief medical officers was a real pleasure and a privilege." Getting cross-Canada support for registry The challenge with getting a network of vaccine registries operating to help with measles and other infectious disease crises in future, Tam says, lies in getting all of the jurisdictions to sign on and co-operate to make their systems speak to one another. "There's in fact quite a lot of work on the way right now to develop those agreements with the provinces, as well as the more technical aspects of this," she said. A national registry, she says, will make things "so much easier" for public health departments, doctors, patients and parents. "That's the most important thing, that you will know whether your kids got the vaccine and that your health provider can have that information as well." Strang says there's agreement on the principle, but "the devil is always in the details." There are a number of groups, including PHAC, working to get the federation to do a better job of sharing health data, he says. "There's certainly support and agreement amongst the chief medical officers and public health leaders of this being a priority," Strang said. But Dr. Iris Gorfinkel, a Toronto family physician and researcher, says she suspects political considerations are behind some of the provinces "literally hoarding their medical data." "When politics stands in the way of science moving forward or health being prioritized, it becomes a serious, potentially life-threatening problem," said Gorfinkel, who is also the founder of PrimeHealth Clinical Research. Some provincial governments may be afraid voters will dislike sharing their health data, she says. But that shouldn't be a factor, given how easy it is to remove identifying details from the information so no one apart from an individual and their health-care provider knows their vaccine status, Gorfinkel says. We're already paying a heavy price — in lives and dollars — for not having a national registry, she says. "First, there's a tremendous waste of vaccines," Gorfinkel said. We saw that during COVID-19, she says, when Canada over-bought vaccines and struggled to administer them before they expired, eventually drawing international criticism for doing so while other parts of the world went without. In the case of the measles outbreaks, she says, "if we don't know where those are happening and we can't ship vaccines to where they're most needed, then what that means is we're not going to make the best use of the vaccines we have." And, of course, people and health systems pay when hospitals fill with people who have become ill from vaccine-preventable illnesses, Gorfinkel says. Looking abroad Other countries have made this work, among them Sweden, France, Finland, Germany, the Netherlands and Spain. In Norway, for example, a national registry that began in 1995 and at first tracked only routine childhood vaccinations, was expanded in 2011 to require mandatory reporting for all vaccines and age groups. Gorfinkel says some of these countries better embrace the sentiment that "what happens to my neighbour does affect me." Public health expert Amir Attaran, a vocal critic of Tam and PHAC during the pandemic, says far more could have been done at the federal level to get a national registry in place in this country, too. WATCH | Tam on why Canada needs better real-time health data: A professor in the faculties of law and school of epidemiology and public health at the University of Ottawa, Attaran says infectious disease experts like Tam have known since the SARS outbreak in 2003 that the country was woefully unprepared to properly track and respond to an outbreak due to poor data sharing. "And because of the experience of SARS in Canada, we should have been very switched on about this," said Attaran, who holds both a law degree and a PhD in biology. He says Canada's Statistics Act empowers the federal government to "require the provinces to cough up statistics," and that's exactly what public health data is. Canada's public health culture is self-defeating, Attaran says, because it recognizes the necessity of accurate and timely data but proceeds "under this false assumption that you can't get those data unless everybody agrees and everybody's happy with it. And then you fail to put in the political energy to bring about that consensus by agreement or coercion." Masking controversy While the pandemic highlighted the need for a national vaccine registry to manage outbreaks better, it also exposed challenges in public health communication. One of the most debated issues was masking. Attaran was among those who said Tam bungled the advice around masking in the earlier stages of the pandemic, for example. "Early in the pandemic, she told people, 'No, you don't need to mask,'" he said. Yet by then the virus had been identified as SARS-CoV-2, and we'd already learned from the 2003 SARS crisis that it required masking, he says. But in Nova Scotia, Strang says, the information scientists were working with early on suggested the virus behaved like an influenza, which spread through droplets, not aerosols. "We don't recommend widespread masking, necessarily, for everybody for influenza." Tam says public health leaders "need to do a better job in explaining to people how the scientific information are coming through, how we analyze it and how we turn them into guidance."

Globe and Mail

7 hours ago

• Globe and Mail

Ovarian Cancer Market Forecast to 2034: Advancing Treatment Frontiers and Epidemiological Shifts

Ovarian cancer remains a significant global health challenge, often diagnosed at an advanced stage due to non-specific symptoms and a lack of effective early screening. It encompasses a spectrum of histological subtypes, including high-grade serous (HGSOC), low-grade serous (LGSOC), and epithelial tumors, each with unique biological and clinical features. High recurrence rates and poor long-term survival continue to drive the urgent need for improved treatment options and earlier detection. DelveInsight's latest report, ' Ovarian Cancer – Market Insight, Epidemiology, and Market Forecast – 2034,' provides a comprehensive overview of the disease's burden across the US, EU4 (Germany, France, Italy, Spain), the UK, and Japan. It offers in-depth segmentation by subtype, stage, age group, and biomarker status, alongside historical and projected epidemiological trends. The analysis highlights rising incidence rates, shifting subtype proportions—particularly serous carcinomas—and the evolving landscape of diagnostic and therapeutic innovation. The ovarian cancer market has transformed in recent years, driven by the expanding use of PARP inhibitors, antiangiogenic agents, and emerging targeted therapies. These options have shifted the treatment paradigm, particularly for BRCA-mutated, HRD-positive, and platinum-sensitive disease. Nonetheless, persistent issues such as chemoresistance, limited options in late-line settings, and variability in biomarker testing are hindering further progress. Looking ahead, the market is anticipated to grow steadily through 2034, propelled by innovations in epigenetic modulators, antibody-drug conjugates (ADCs), immune-oncology combinations, and advanced diagnostics like liquid biopsies. Enhanced biomarker testing and personalized treatment strategies will support optimized patient care. DelveInsight's full report explores pipeline highlights, market drivers and barriers, and strategic recommendations for stakeholders aiming to transform the outlook for ovarian cancer patients. Request a sample and uncover the latest breakthroughs shaping the Ovarian Cancer market landscape and future outlook Some of the key insights of the Ovarian Cancer Market Report: • In 2024, the ovarian cancer market in the 7MM was valued at USD 2.7 billion. • Market size is expected to grow with the launch of new ovarian cancer therapies. • The U.S. held the largest share, reaching USD 1.92 billion in 2024. • Total incident ovarian cancer cases in the 7MM were 61K in 2024. • The U.S. reported the highest number of high and low-grade serous ovarian cancer cases. • There were approximately 37.6K serous ovarian cancer cases in the 7MM in 2024. • In January 2025, IPS HEART received Orphan Drug Designation (ODD) from the FDA for GIVI-MPCs, recognizing their potential to create new muscle with full-length dystrophin in Becker Muscular Dystrophy (BMD). The therapy has shown promising results in generating human muscle with full-length dystrophin in dystrophic pigs, young and aged Duchenne Muscular Dystrophy (DMD) mice, and an Ovarian Cancer mouse model. • In April 2025, Biocon Biologics received FDA approval for JOBEVNE (bevacizumab-nwgd), a biosimilar to Avastin®, for intravenous use. JOBEVNE is approved for multiple cancers, including metastatic colorectal cancer, non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, advanced cervical cancer, and ovarian, fallopian tube, or primary peritoneal cancer. • In February 2025, the FDA granted fast-track designation to CUSP06, a CDH6-directed antibody-drug conjugate (ADC), for the treatment of patients with platinum-resistant ovarian cancer. • Emerging therapies for ovarian cancer include Avutometinib + defactinib, Relacorilant, IMFINZI, Rinatabart sesutecan, Olvimulogene nanivacirepvec, Nemvaleukin alfa, Catequentinib, Raludotatug deruxtecan, Luveltamab Tazevibulin, Sacituzumab tirumotecan, Azenosertib (ZN-c3) + Niraparib, TORL-1-23, and others. • Key companies involved in the treatment of ovarian cancer include Genmab, AstraZeneca, On Target Laboratories, Chipscreen Biosciences, Aravive, Inc., Allarity Therapeutics, Merck KGaA, GlaxoSmithKline, Aprea Therapeutics, Verastem, Inc., Ellipses Pharma, Impact Therapeutics, Inc., BeiGene, Apexigen, Novartis Oncology, VBL Therapeutics, Cristal Therapeutics, Bayer, Regeneron Pharmaceuticals, DCPrime BV, AIM ImmunoTech Inc., Pharmicell Co., Ltd., Shattuck Labs, Inc., Laekna Limited, Celsion, and others. Curious to see the graphical version of these numbers? The ovarian cancer infographic is ready for you. Check it out here! Ovarian Cancer Overview Ovarian cancer is a complex and often late-diagnosed malignancy arising from the epithelial cells, stromal cells, or germ cells of the ovary. Among these, epithelial ovarian cancer is the most prevalent, accounting for over 90% of malignant ovarian tumors. Due to its subtle early symptoms and lack of reliable screening methods, the disease is frequently diagnosed at advanced stages, contributing to its high mortality rate among gynecological cancers. The most common and aggressive subtype is High-Grade Serous Ovarian Cancer (HGSOC), which often presents with widespread peritoneal metastases. In contrast, Low-Grade Serous Ovarian Cancer (LGSOC) tends to follow a more indolent course but shows resistance to standard chemotherapy, highlighting a critical unmet need for targeted therapies. Genetic mutations such as BRCA1/2 and alterations in the MAPK pathway (BRAF/KRAS/NRAS/NF1) and homologous recombination deficiency (HRD) status play a pivotal role in disease stratification and therapy selection. Over the past decade, the ovarian cancer treatment landscape has evolved with the introduction of PARP inhibitors, anti-angiogenic agents, and targeted therapies that have significantly improved outcomes in biomarker-driven subpopulations. Despite these advancements, resistance development, limited options for certain subtypes like LGSOC, and high relapse rates continue to challenge long-term disease control. As research progresses, efforts are focused on improving early diagnosis, personalizing treatment based on molecular profiling, and expanding therapeutic options through clinical trials and novel drug development. Get a free sample for the Ovarian Cancer market forecast, size & share analysis report: Ovarian Cancer Epidemiology The epidemiology section offers an overview of historical, current, and projected trends in the seven major countries (7MM) from 2020 to 2034. It helps identify the factors influencing these trends by examining various studies and perspectives from key opinion leaders. Additionally, the section provides an in-depth analysis of the diagnosed patient population and future trends. Ovarian Cancer Epidemiology Segmentation: The Ovarian Cancer market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into: • Total incident cases of Ovarian Cancer • Age-specific cases of Ovarian Cancer • Type-Specific Cases of Ovarian Cancer • Stage-specific Cases of high and Low-Grade Serous Ovarian Cancer • Biomarker-specific Cases of high and Low-Grade Serous Ovarian Cancer Ovarian Cancer Drugs Uptake and Pipeline Development Activities The Drug Uptake section offers a detailed analysis of the adoption trends of newly launched and upcoming therapies for Ovarian Cancer throughout the study period. It evaluates patient adoption rates, market penetration, and the commercial performance of each therapy, providing a clear understanding of the factors driving or hindering the market acceptance of these treatments. The Therapeutics Assessment further highlights the Ovarian Cancer drugs, demonstrating the most rapid uptake. It examines the underlying drivers contributing to their swift adoption and compares the market share of these therapies to identify those gaining significant traction. Additionally, the report provides an in-depth overview of the current therapeutic pipeline for Ovarian Cancer, covering investigational drugs at various stages of development. It profiles the key pharmaceutical and biotech companies actively involved in advancing targeted treatments and presents the latest updates on partnerships, mergers and acquisitions, licensing deals, and other strategic developments shaping the future of Ovarian Cancer therapeutics. Ovarian Cancer Market Outlook The ovarian cancer treatment landscape is undergoing a significant transformation, with the integration of targeted therapies, personalized medicine, and ongoing clinical research aimed at improving long-term outcomes. High-grade serous ovarian cancer (HGSOC), the most prevalent subtype, continues to be treated with a combination of surgery and platinum-based chemotherapy. However, the emergence of maintenance therapies—especially PARP inhibitors—has reshaped post-treatment strategies for patients with BRCA or HRD mutations, helping reduce recurrence rates and extend progression-free survival. The future of ovarian cancer care is increasingly personalized, with clinical trials exploring novel options like immunotherapy, vaccine-based approaches, and radiation strategies for advanced or recurrent disease. These innovations reflect a broader trend toward therapies tailored to molecular profiles and disease stage, moving away from one-size-fits-all treatment. However, disparities in access to care remain a major challenge. Socioeconomic, racial, and geographic barriers often limit timely diagnosis and appropriate treatment, particularly in underserved populations. As awareness of BRCA testing and biomarker-driven treatment grows, expanding access to genetic screening and oncology expertise will be crucial. The ovarian cancer market is expected to expand steadily through 2034, driven by rising disease burden, evolving therapeutic options, and a growing emphasis on precision medicine. Addressing current gaps in care delivery, especially among high-risk and underserved groups, will be essential to unlocking the full potential of these medical advancements. Ovarian Cancer Market Drivers • The introduction of PARP inhibitors (e.g., olaparib, niraparib) and other targeted agents based on BRCA and HRD status has revolutionized ovarian cancer treatment, improving survival and reducing recurrence in select patient groups. • Increasing adoption of genetic and molecular testing for BRCA mutations, HRD status, and other biomarkers is enabling personalized treatment strategies, driving demand for advanced therapeutic options. Ovarian Cancer Market Barriers • The absence of reliable early screening methods and vague initial symptoms often lead to diagnosis at advanced stages, limiting curative treatment options and affecting patient outcomes. • Limited access to specialized oncology care, especially in rural and low-income regions, along with underutilization of genetic testing among minority populations, continues to hinder equitable treatment and diagnosis. Scope of the Ovarian Cancer Market Report • Study Period: 2020–2034 • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]. • Key Ovarian Cancer Companies: Genmab, AstraZeneca, On Target Laboratories, Chipscreen Biosciences, Aravive, Inc., Allarity Therapeutics, Merck KGaA, GlaxoSmithKline, Aprea Therapeutics, Verastem, Inc., Ellipses Pharma, Impact Therapeutics, Inc., BeiGene, Apexigen, Novartis Oncology, VBL Therapeutics, Cristal Therapeutics, Bayer, Regeneron Pharmaceuticals, DCPrime BV, AIM ImmunoTech Inc., Pharmicell Co., Ltd., Shattuck Labs, Inc., Laekna Limited, Celsion, and others. • Key Ovarian Cancer Therapies: Avutometinib + defactinib, Relacorilant, IMFINZI, Rinatabart sesutecan, Olvimulogene nanivacirepvec, Nemvaleukin alfa, Catequentinib, Raludotatug deruxtecan, Luveltamab Tazevibulin, Sacituzumab tirumotecan, Azenosertib (ZN-c3) + Niraparib, TORL-1-23, and others. • Ovarian Cancer Therapeutic Assessment: Ovarian Cancer currently marketed, and Ovarian Cancer emerging therapies. • Ovarian Cancer Market Dynamics: Ovarian Cancer market drivers and Ovarian Cancer market barriers. • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies. • Ovarian Cancer Unmet Needs, KOL's views, Analyst's views, Ovarian Cancer Market Access and Reimbursement. Table of Contents 1. Ovarian Cancer Market Report Introduction 2. Executive Summary for Ovarian Cancer 3. SWOT analysis of Ovarian Cancer 4. Ovarian Cancer Patient Share (%) Overview at a Glance 5. Ovarian Cancer Market Overview at a Glance 6. Ovarian Cancer Disease Background and Overview 7. Ovarian Cancer Epidemiology and Patient Population 8. Country-Specific Patient Population of Ovarian Cancer 9. Ovarian Cancer Current Treatment and Medical Practices 10. Ovarian Cancer Unmet Needs 11. Ovarian Cancer Emerging Therapies 12. Ovarian Cancer Market Outlook 13. Country-Wise Ovarian Cancer Market Analysis (2020–2034) 14. Ovarian Cancer Market Access and Reimbursement of Therapies 15. Ovarian Cancer Market Drivers 16. Ovarian Cancer Market Barriers 17. Ovarian Cancer Appendix 18. Ovarian Cancer Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve. Media Contact Company Name: DelveInsight Contact Person: Jatin Vimal Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: Nevada Country: United States Website: